In the past few years, cell-derived membrane vesicle-based
tumor vaccines have been considered as valuable new tools for
cancer immunotherapy. Despite promising results in
cancer clinical trails, an improved method is urgently needed for high efficiency
tumor vaccines for a broad spectrum of
tumors. Here we developed a single membrane vesicle-based
vaccine, which is active in repressing both
melanoma (B16) and
Lewis lung carcinoma (LLC)
tumor growth. By using the intrinsic function of dendritic cells in the processing and presentation of
antigens, we generated dendritic cell (DC)-derived membrane vesicles (DC-mv) bearing
tumor antigens from both B16 and LLC cells. Vaccination with this DC-mv-based dual
vaccine induced specific cytotoxic T lymphocytes (CTL)-dependent
tumor rejection and suppressed the growth of both types of
tumor xenografts in mice. In addition, induction of CTL by this
vaccine resulted in cross-protection responses and consequently enabled significant enhanced anti-
tumor effects, indicating the synergistic anti-
tumor activity. Our study suggests that the DC-mv-based
vaccine holds great potential as a highly effective, versatile, cell-free
vaccine for inhibition of multiple types of
tumor growth.